Novavax Inc. closed 62.24% below its 52-week high of $23.86, which the company reached on June 6th.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Novavax Inc. closed 60.94% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of ...

The most recent trading session ended with Novavax (NVAX) standing at $9.34, reflecting a +1.3% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 1.46%.

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%.

SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6 ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the ...